Evidence map›Paper›PMID 17204705›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2007

Human biodistribution and radiation dosimetry of the tachykinin NK1 antagonist radioligand [18F]SPA-RQ: comparison of thin-slice, bisected, and 2-dimensional planar image analysis.

David R Sprague, Frederick T Chin, Jeih-San Liow, Masahiro Fujita, H Donald Burns, Richard Hargreaves, James B Stubbs, Victor W Pike, Robert B Innis, P David Mozley

Open access · greenAbstract read
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 28 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. First-in-human Evaluation of Safety and Dosimetry of [Molecular imaging and biology · 2025
    Article
  5. Dosimetry of [medRxiv : the preprint server for health sciences · 2024
    Article
  6. Biodistribution, Dosimetry, and Pharmacokinetics ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023
    Article
  7. [Scientific reports · 2019
    Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

David R SpragueMolecular Imaging Branch, NIMH, National Institutes of Health, Bethesda, Maryland 20892-0135, USA.
Frederick T Chin
Jeih-San Liow
Masahiro Fujita
H Donald Burns
Richard Hargreaves
James B Stubbs
Victor W Pike
Robert B Innis
P David Mozley
National Institutes of Health · US

Funding

PET Radiopharmaceutical SciencesZ01MH002793 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI PIKE, VICTOR W · 2002 to 2008
$7.4M
Clinical Evaluation of PET RadiotracersZ01MH002852 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI INNIS, ROBERT · 2005 to 2008
$4.4M
Preclinical Evaluation Of PET RadiotracersZ01MH002795 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI INNIS, ROBERT · 2002 to 2008
$3.2M
Intramural NIH HHS Z01 MH002852
6 · The paper itself

Abstract

unlabelled(18)F-Labeled substance P antagonist-receptor quantifier ([(18)F]SPA-RQ) [2-fluoromethoxy-5-(5-trifluoromethyl-tetrazol-1-yl)-benzyl]-[(2S,3S)-2-phenyl-piperidin-3-yl)amine] is a selective radioligand for in vivo quantification of tachykinin NK(1) receptors with PET. The aims of this study were to estimate the radiation safety profile and relative risks of [(18)F]SPA-RQ with 3 different methods of image analysis.

methodsWhole-body PET images were acquired in 7 healthy subjects after injection of 192 +/- 7 MBq (5.2 +/- 0.2 mCi) [(18)F]SPA-RQ. Emission images were serially acquired at multiple time-points from 0 to 120 min and approximately 180-240 min after injection. Urine samples were collected after each imaging session and for 24 h after the last scan to measure excreted radioactivity. Horizontal tomographic images were compressed to varying degrees in the anteroposterior direction to create 3 datasets: thin-slice, bisected, and 2-dimensional (2D) planar images. Regions of interest were drawn around visually identifiable source organs to generate time-activity curves for each dataset. Residence times were determined from these curves, and doses to individual organs and the body as a whole were calculated using OLINDA/EXM 1.0.

resultsThe lungs, upper large intestine wall, small intestine, urinary bladder wall, kidneys, and thyroid had the highest radiation-absorbed doses. Biexponential fitting of mean bladder and urine activity showed that about 41% of injected activity was excreted via urine. Assuming a 2.4-h urine voiding interval, the calculated effective doses from thin-slice, bisected, and 2D planar images were 29.5, 29.3, and 32.3 microSv/MBq (109, 108, and 120 mrem/mCi), respectively.

conclusionInsofar as effective dose is an accurate measure of radiation risk, all 3 methods of analysis provided quite similar estimates of risk to human subjects. The radiation dose was moderate and would potentially allow subjects to receive multiple PET scans in a single year. Individual organ exposures varied among the 3 methods, especially for structures asymmetrically located in an anterior or posterior position. Bisected and 2D planar images almost always provided higher organ dose estimates than thin-slice images. Thus, either the bisected or 2D planar method of analysis appears acceptable for quantifying human radiation burden, at least for radioligands with a relatively broad distribution in the body and not concentrated in a small number of radiation sensitive organs.

Indexed as

Neurokinin-1 Receptor AntagonistsFluorine RadioisotopesHumansImage Processing, Computer-AssistedMalePhantoms, ImagingPiperidinesPositron-Emission TomographyRadiometryRadiopharmaceuticalsRiskSoftwareTetrazolesTime FactorsTomography, X-Ray ComputedWhole Body Imaging(2-fluoromethoxy-5-(5-trifluoromethyltetrazol-1-yl)benzyl)(2-phenylpiperidin-3-yl)amineFluorine RadioisotopesNeurokinin-1 Receptor AntagonistsPiperidinesRadiopharmaceuticalsTetrazoles

Identifiers

PMID17204705
PMCPMC4135382
OpenAlexW2127499858

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.